Skip to Main Content
Access your saved content
Tom Herd, managing partner of Accenture’s M&A practice and Arda Ural, senior manager in Accenture’s Life Sciences Strategy practice, talk about why consolidation is likely in the biopharmaceutical industry. They argue that the industry faces an uncertain future, while many companies have strong cash positions—a strong indication that M&A activity is likely to pick up.
In this podcast, Herd and Ural argue that biopharmaceutical companies can build better shareholder value by being focused about their acquisition targets.
Download Video Podcast [MP4, 13.5MB] [Running time 8:10]
Download Audio Podcast [MP3, 7.27MB] [Running time 7:56]
Subscribe to Podcast Series
April 18, 2011
Skip Footer Links